Structure Therapeutics is trading 4.1% down now at $51.19 as investors continue to lock in gains after a powerful rally driven by bullish oral GLP-1 obesity data and financing news.
- The stock recently surged following positive Phase 2 results for aleniglipron and a significant capital raise.
- Today’s decline is characterized as a technical pullback and sentiment reset rather than a reaction to fresh company-specific news.